Decreased MACC 1 expression in osteosarcoma cells reverses the decline of dendritic cells activation and the cytotoxicity

Objective: Metastasis-associated in colon cancer-1 (MACC1), a novel protein highly expressed in a variety of cancers, is closely related to tumor progression, metastasis and prognosis. Dendritic cells (DCs) can be activated by exogenous tumor antigens to kill tumor cells directly. The purpose of this study was to investigate the effect of MACC1 in osteosarcoma cells on DCs activation and cytotoxicity. Methods: MACC1 gene expression was determined by RT-qPCR in four osteosarcoma cell lines, in which 143B cells expressed the highest level of MACC1, and were selected as the target cell line. By lentivirus infection generating MACC1 shRNA, MACC1 was knocked downed in 143B cells (143B-i cells). Human DCs, isolated from PBMCs, were divided into four groups: i) control group (no stimulation); ii) DCs group (with stimulation); iii) DCs/143B group (DCs and 143B cells were co-cultured); and iv) DCs/143B group (DCs and 143B-i cells were co-cultured). Results: Co-culture of DCs with 143B cells inhibited DCs activation and decreased DCs induced cytotoxity as evidenced by reduced DCs activation markers expression, IL12 secretion and LDH release. However, MACC1 knockdown reversed the above-mentioned effects. Furthermore, the immunofluorescence indicating the endocytosis of 143B cell fragments into DCs was decreased by MACC1 knockdown. Conclusion: This study suggests the recovered activation and cytotoxicity of DCs by MACC1 knockdown in osteosarcoma cells.

[1]  Guoying Miao,et al.  MACC1 facilitates chemoresistance and cancer stem cell-like properties of colon cancer cells through the PI3K/AKT signaling pathway , 2017, Molecular medicine reports.

[2]  D. Gabrilovich,et al.  Dendritic cells in cancer: the role revisited. , 2017, Current opinion in immunology.

[3]  S. Nierkens,et al.  Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses. , 2016, Critical reviews in oncology/hematology.

[4]  E. Kopczynska The potential therapeutic applications and prognostic significance of metastasis-associated in colon cancer-1 (MACC1) in cancers , 2016, Contemporary oncology.

[5]  M. Bittman,et al.  Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets. , 2016, Current problems in pediatric and adolescent health care.

[6]  Jianguang Wang,et al.  RNAi-mediated silencing of AQP1 expression inhibited the proliferation, invasion and tumorigenesis of osteosarcoma cells , 2015, Cancer biology & therapy.

[7]  T. Daemen,et al.  Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy , 2015, Oncoimmunology.

[8]  R. Consolini,et al.  Dendritic cell defects in the colorectal cancer , 2014, Human vaccines & immunotherapeutics.

[9]  E. Tartour,et al.  Control of the Immune Response by Pro-Angiogenic Factors , 2014, Front. Oncol..

[10]  Huimin Zhu,et al.  High expression of MACC1 predicts poor prognosis in patients with osteosarcoma , 2014, Tumor Biology.

[11]  Peter M. Schlag,et al.  Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer , 2013, Molecular oncology.

[12]  Yijiang Chen,et al.  MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer , 2013, Medical Oncology.

[13]  H. Janssen,et al.  Hepatitis B Virus Lacks Immune Activating Capacity, but Actively Inhibits Plasmacytoid Dendritic Cell Function , 2011, PloS one.

[14]  L. Qin,et al.  Targeting the osteosarcoma cancer stem cell , 2010, Journal of orthopaedic surgery and research.

[15]  K. Zänker,et al.  BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation. , 2010, Cellular immunology.

[16]  K. Moriyama,et al.  GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). , 2009, Blood.

[17]  M. Lederman,et al.  Impaired Plasmacytoid Dendritic Cell (PDC)-NK Cell Activity in Viremic Human Immunodeficiency Virus Infection Attributable to Impairments in both PDC and NK Cell Function , 2009, Journal of Virology.

[18]  Zhan-qing Zhang,et al.  HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. , 2009, Molecular immunology.

[19]  B. Trinité,et al.  Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. , 2008, Cancer research.

[20]  Y. Iwamoto,et al.  Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy , 2008, Reviews on recent clinical trials.

[21]  R. Gorlick,et al.  Therapy for Osteosarcoma , 2008, Paediatric drugs.

[22]  E. Madon,et al.  Interactions between osteosarcoma cell lines and dendritic cells immune function: An in vitro study. , 2008, Cellular immunology.

[23]  A. Landay,et al.  Dendritic cell activation and maturation induced by mucosal fluid from women with bacterial vaginosis. , 2007, Clinical immunology.

[24]  B. Trinité,et al.  Immature CD4−CD103+ Rat Dendritic Cells Induce Rapid Caspase-Independent Apoptosis-Like Cell Death in Various Tumor and Nontumor Cells and Phagocytose Their Victims1 , 2005, The Journal of Immunology.

[25]  K. Tamada,et al.  In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. , 2000, Blood.

[26]  K. Schooley,et al.  Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) , 1999, The Journal of experimental medicine.

[27]  M. Onji,et al.  Production of antibody to hepatitis B surface antigen (anti‐HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells , 1997, Immunology.